Multiple studies have revealed that the response rate of PD‐1/PD‐L1 inhibitors in second‐line treatment of unscreened NSCLC is merely approximately 20%.7, 8, 9, 10, 11 Meanwhile, in selected NSCLC patients with PD‐L1 expression ≥ 50%, the response rate of pembrolizumab in first‐line treatment can reach 44.8%.9 The CHECKMATE‐026 study focusing on nivolumab in NSCLC first‐line treatment showed no significant improvement in the nivolumab compared to the chemotherapy cohort (PFS 4.2 vs. 5.9 months; OS 14.4 vs. 13.2 months). This evidence concerns the gene CD274 and non-small cell lung carcinoma.